A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Methods Over 1548 RCTs on the use of UDCA as the treatment for NASH, from 2004 to 2018 have been reviewed. Estimation of the total subject populations in all these studies approximates almost 15,000 NASH patients. Outcome measures include both decreases in liver transaminases and improvement in histology. All the RCTs, even the current guidelines, offer different options, including the use of UDCA. Follow-up periods range from 4 weeks to 96 weeks. Results Of all the 1548 RCTs reviewed fromdoi:10.1136/gutjnl-2019-iddfabstracts.297 fatcat:bt4qyrbq3vak7b4wrpgrzvqr7e